参考文献/References:
[1] Chyu KY, Shah PK. HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis[J]. Front Pharmacol,2015,6:187.
[2] Kingwell BA, Chapman MJ, Kontush A,et al. HDL-targeted therapies:progress, failures and future[J]. Nat Rev Drug Discov,2014,13(6):445-464.
[3] Wang M,Briggs MR. HDL:the metabolism, function,and therapeutic importance[J]. Chem Rev,2004,104(1):119-137.
[4] Jacobson TA, Ito MK,Maki KC,et al. National Lipid Association recommendations for patient-centered management of dyslipidemia:part 1—executive summary[J].J Clin Lipidol,2014,8(5):473-488.
[5] Goyal P, Igel LI, LaScalea K,et al. Cardiometabolic impact of non-statin lipid low-ering therapies[J]. Curr Atheroscler Rep,2014,16:390.
[6] Sando KR,Michelle Knight P.Nonstatin therapies for management of dyslipidemia: a review[J]. Clin Ther,2015,37(10):2153-2179.
[7] Gomaraschi M, Adorni MP, Banach M, et al. Effects of established hypolipidemic drugs on HDL concentration, subclass distribution,and function[J].Handb Exp Pharmacol,2015,224:593-615.
[8] Rubins HB,Robins SJ,Collins D,et al.Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol.Veterans Affairs High-density Lipoprotein Cholesterol Intervention Trial Study Group[J].N Engl J Med,1999,341(6):410-418.
[9] Ginsberg HN. The ACCORD(Action to Control Cardiovascular Risk in Diabetes)Lipid Trial: What we learn from subgroup analyses[J]. Diabetes Care,2011,34(Suppl 2):S107-108.
[10] Yadav R,Liu Y,Kwok S,et al.Effect of extended-release niacin on high-density lipoprotein(HDL)functionality, lipoprotein metabolism, and mediators of vascular inflammation in statin-treated patients[J]. J Am Heart Assoc,2015,4(9):e001508.
[11] Mani P,Rohatgi A.Niacintherapy, HDL cholesterol, and cardiovascular disease: is the HDL hypothesis defunct? [J]. Curr Atheroscler Rep,2015,17(8):521.
[12] Zeman M, Vecka M, Perlík F, et al. Niacin in the treatment of hyperlipidemias in light of new clinical trials:has niacin lost its place?[J]. Med Sci Monit,2015,21:2156-2162.
[13] Keene D, Price C, Shun-Shin MJ, et al.Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin,fibrates,and CETP inhibitors: meta-analysis of randomized controlled trials including 117 411 patients[J]. BMJ, 2014,349:g4379.
[14] Krause BR, Remaley AT. Reconstituted HDL for the acute treatment of acute coronary syndrome[J].Curr Opin Lipidol,2013,24(6):480-486.
[15] Hafiane A, Kellett S, Genest J. Treatment options for low high-density lipoproteins[J]. Curr Opin Endocrinol Diabetes Obes,2014,21(2):134-139.
[16] Joy TR. Novel HDL-based therapeutic agents[J]. Pharmacol Ther,2012,135(1):18-30.
[17] Bishop Bryan M. Systematic review of CETP inhibitors for increasing high-density lipoprotein cholesterol: where do these agents stand in the approval process?[J]. Am J Ther,2015,22(2):147-158.
[18] Hovingh GK, Kastelein JJ, van Deventer SJ, et al. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia(TULIP):a randomised, double-blind, placebo-controlled phase 2 trial[J]. Lancet,2015,386(9992): 452-460.
[19] Ford J,Lawson M,Fowler D,et al.Tolerability,pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein(CETP)inhibitor, in healthy subjects[J]. Br J Clin Pharmacol,2014,78(3):498-508.
[20] Rittershaus CW,Miller DP,Thomas LJ, et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic:lesions in a rabbit model of atherosclerosis[J]. Arterioscler Thromb Vasc Biol,2000,20(9):2106-2112.
[21] Salazar-González JA,Rosales-Mendoza S. A perspective for atherosclerosis vaccination:is there a place for plant-based vaccines?[J]. Vaccine,2013,31(10):1364-1349.
[22] Liaw YW, Lin CY, Lai YS, et al.A vaccine targeted at CETP alleviates high fat and high cholesterol diet-induced atherosclerosis and non-alcoholic steatohepatitis in rabbit[J]. PLoS One,2014,9(12):e111529.
[23] Scharnagl H,Heuschneider C,Sailer S,et al. Decreased cholesterol efflux capacity in patients with low cholesteryl ester transfer protein plasma levels[J]. Eur J Clin Invest,2014,44(4):395-401.
[24] Mousa SS, Block RC, Mousa SA. High density lipoprotein(HDL)modulation targets[J]. Drugs Future,2010,35(1):33-39.
[25] Peng D,Hiipakka RA,Dai Q, et al.Antiatherosclerotic effects of a novel synthetic tissue-selective steroidal liver X receptor agonist in low-density lipoprotein receptor-deficient mice[J]. J Pharmacol Exp Ther,2008,327(2):332-342.
[26] Pfeifer T, Buchebner M, Chandak PG, et al.Synthetic LXR agonist suppresses endogenous cholesterol biosynthesis and efficiently lowers plasma cholesterol[J]. Curr Pharm Biotechnol,2011,12(2):285-292.
[27] Fievet C,Staels B.Liver X receptor modulators:effects on lipid metabolism and potential use in the treatment of atherosclerosis[J].Biochem Pharmacol,2009,77(8): 1316-1327.
[28] Omidi A,Ansarinik H,Ghazaghi M. Prosopis farcta beans increase HDL cholesterol and decrease LDL cholesterol in ostriches( Struthio camelus )[J]. Trop Anim Health Prod,2013,45(2):431-434.
[29] McEneny J,Wade L,Young IS,et al.Lycopene intervention reduces inflammation and improves HDL functionality in moderately overweight middle-aged individuals[J]. J Nutr Biochem,2013,24(1):163-168.
[30] van de Woestijne AP,van der Graaf Y,Liem AH,et al.Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication[J]. J Am Coll Cardiol,2013,62(20):1834-1841.
[31] Rohatgi A. High-density lipoprotein function measurement in human studies: focus on cholesterol efflux capacity[J]. Prog Cardiovasc Dis,2015,58(1):32-40.